Physician profile
Ajay Pabby
NPI 1205929163
$6,484.06
in general payments reported to CMS, 2019-2025
29 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $385 · 2021: $360 · 2022: $925 · 2023: $1,688 · 2024: $881 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,602 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,601.70 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,765.08 | 2019-2025 | Exalt Model D, Cre Pro, X-Tack Endoscopic Helix Tacking System |
| Abbvie INC. | $958.23 | 2019-2025 | |
| Cook Medical LLC | $642.96 | 2019-2024 | Hemospray |
| Takeda Pharmaceuticals U.S.A., INC. | $509.10 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $456.80 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $281.93 | 2019-2023 | Stelara |
| Regeneron Healthcare Solutions, INC. | $235.29 | 2022-2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.04 | 2019-2025 | Xifaxan, Plenvu |
| Braintree Laboratories, INC. | $175.11 | 2019-2025 | Suflave |
| Mauna Kea Technologies, INC. | $157.36 | 2019 | |
| Conmed Corporation | $147.77 | 2025 | Conmed Biliary, Conmed Dilation |
| Intercept Pharmaceuticals, INC. | $125.73 | 2021-2024 | Ocaliva |
| Pfizer INC. | $125.48 | 2019-2024 | |
| Medtronic, INC. | $103.69 | 2025 | Pillcam |
| Endogastric Solutions, INC | $88.30 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $82.14 | 2025 | Capsocam Plus |
| Gilead Sciences, INC. | $73.04 | 2019-2020 | |
| Ucb, INC. | $60.30 | 2020-2022 | |
| Allergan, INC. | $50.47 | 2019 | |
| Pharmacosmos Therapeutics INC. | $44.84 | 2023 | Monoferric |
| Genzyme Corporation | $40.39 | 2023 | |
| Merck Sharp & Dohme LLC | $36.26 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $29.38 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $27.68 | 2025 | Rezdiffra |
| Ardelyx, INC. | $21.03 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $18.19 | 2022 | |
| Shire North American Group INC | $16.70 | 2019 | |
| Abbott Laboratories | $12.29 | 2022 | |
| Ferring Pharmaceuticals INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Pabby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.